Please wait while we load the requested 10-Q report or click the link below:
For Immediate Release
Contact: Alfred Merriweather
VP, Finance and CFO
ACLARA ANNOUNCES THIRD QUARTER 2004 FINANCIAL RESULTS
MOUNTAIN VIEW, Calif. November 9, 2004 ACLARA BioSciences (Nasdaq: ACLA), today reported financial results for the three and nine months ended September 30, 2004.
Third Quarter 2004 Financial Results
Revenue for the three months ended September 30, 2004 was $181,000, compared to revenue for the three months ended September 30, 2003 of $276,000. For the first nine months of 2004, revenue was $1.3 million compared to $860,000 in the comparable prior year period.
Total operating expenses for the three months ended September 30, 2004 were $4.7 million, compared to $5.6 million in the comparable quarter of 2003. Included in expenses in the third quarter of 2004 were $248,000 of legal, financial advisory and accounting expenses related to the proposed merger with ViroLogic, Inc.
The net loss for the three months ended September 30, 2004 was $4.1 million, or a loss of $0.11 per share, compared to a net loss of $4.9 million, or $0.14 per share in the third quarter of 2003. Excluding merger-related expenses and reflecting the Companys continued expense control efforts, net loss for the three months ended September 30, 2004 was $3.8 million, a decrease of 22% from the third quarter of 2003.
For the first nine months of 2004, the net loss was $12.7 million, or a loss of $0.35 per share, compared to a net loss of $16.3 million, or a loss of $0.46 per share, for the first nine months of 2003.
Total cash resources, comprising cash, cash equivalents and marketable investments, were $78.6 million at September 30, 2004. The reduction in these balances during the third quarter was $3.2 million.
Recent progress in ACLARAs business includes:
|||Proposed Merger with ViroLogic, Inc.: On June 1, we announced that we had signed a definitive merger agreement with ViroLogic. This proposed merger will combine ViroLogics established infrastructure and experience in commercializing technologies for personalized medicine in the HIV market with ACLARAs technology applicable to the substantially larger cancer market. On October 19, we announced some changes to the terms of the merger. The merger is expected to be completed shortly after the meetings of stockholders that are scheduled for December 10 to vote on the merger and related matters.|
The following information was filed by Aclara Biosciences Inc on Tuesday, November 9, 2004 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Aclara Biosciences Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Aclara Biosciences Inc.